Sweden · Delayed Price · Currency is SEK BioGaia AB Statistics
Total Valuation
BioGaia AB has a market cap or net worth of SEK 12.33 billion. The enterprise value is 11.81 billion.
| Market Cap | 12.33B |
| Enterprise Value | 11.81B |
Important Dates
The last earnings date was Thursday, October 22, 2026.
| Earnings Date | Oct 22, 2026 |
| Ex-Dividend Date | May 8, 2026 |
Share Statistics
BioGaia AB has 101.16 million shares outstanding. The number of shares has increased by 0.02% in one year.
| Current Share Class | 98.50M |
| Shares Outstanding | 101.16M |
| Shares Change (YoY) | +0.02% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 5.52% |
| Owned by Institutions (%) | 44.26% |
| Float | 83.94M |
Valuation Ratios
The trailing PE ratio is 31.50 and the forward PE ratio is 25.62.
| PE Ratio | 31.50 |
| Forward PE | 25.62 |
| PS Ratio | 7.36 |
| PB Ratio | 9.96 |
| P/TBV Ratio | 11.46 |
| P/FCF Ratio | 47.10 |
| P/OCF Ratio | 42.78 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 23.70, with an EV/FCF ratio of 45.10.
| EV / Earnings | 29.76 |
| EV / Sales | 7.04 |
| EV / EBITDA | 23.70 |
| EV / EBIT | 24.95 |
| EV / FCF | 45.10 |
Financial Position
The company has a current ratio of 5.14, with zero debt.
| Current Ratio | 5.14 |
| Quick Ratio | 2.57 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | 314.02 |
Financial Efficiency
Return on equity (ROE) is 32.10% and return on invested capital (ROIC) is 54.57%.
| Return on Equity (ROE) | 32.10% |
| Return on Assets (ROA) | 19.86% |
| Return on Invested Capital (ROIC) | 54.57% |
| Return on Capital Employed (ROCE) | 37.37% |
| Weighted Average Cost of Capital (WACC) | 5.53% |
| Revenue Per Employee | 6.59M |
| Profits Per Employee | 1.56M |
| Employee Count | 251 |
| Asset Turnover | 1.13 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, BioGaia AB has paid 101.84 million in taxes.
| Income Tax | 101.84M |
| Effective Tax Rate | 20.64% |
Stock Price Statistics
The stock price has increased by +21.17% in the last 52 weeks. The beta is 0.23, so BioGaia AB's price volatility has been lower than the market average.
| Beta (5Y) | 0.23 |
| 52-Week Price Change | +21.17% |
| 50-Day Moving Average | 116.00 |
| 200-Day Moving Average | 116.71 |
| Relative Strength Index (RSI) | 55.10 |
| Average Volume (20 Days) | 231,378 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BioGaia AB had revenue of SEK 1.65 billion and earned 391.56 million in profits. Earnings per share was 3.87.
| Revenue | 1.65B |
| Gross Profit | 1.20B |
| Operating Income | 466.95M |
| Pretax Income | 493.39M |
| Net Income | 391.56M |
| EBITDA | 483.82M |
| EBIT | 466.95M |
| Earnings Per Share (EPS) | 3.87 |
Balance Sheet
The company has 518.28 million in cash and no debt, with a net cash position of 518.28 million or 5.12 per share.
| Cash & Cash Equivalents | 518.28M |
| Total Debt | n/a |
| Net Cash | 518.28M |
| Net Cash Per Share | 5.12 |
| Equity (Book Value) | 1.22B |
| Book Value Per Share | 12.08 |
| Working Capital | 835.31M |
Cash Flow
In the last 12 months, operating cash flow was 284.45 million and capital expenditures -26.07 million, giving a free cash flow of 258.38 million.
| Operating Cash Flow | 284.45M |
| Capital Expenditures | -26.07M |
| Depreciation & Amortization | 16.86M |
| Net Borrowing | -7.06M |
| Free Cash Flow | 258.38M |
| FCF Per Share | 2.55 |
Margins
Gross margin is 72.74%, with operating and profit margins of 28.22% and 23.67%.
| Gross Margin | 72.74% |
| Operating Margin | 28.22% |
| Pretax Margin | 29.82% |
| Profit Margin | 23.67% |
| EBITDA Margin | 29.24% |
| EBIT Margin | 28.22% |
| FCF Margin | 15.62% |
Dividends & Yields
This stock pays an annual dividend of 4.00, which amounts to a dividend yield of 3.28%.
| Dividend Per Share | 4.00 |
| Dividend Yield | 3.28% |
| Dividend Growth (YoY) | -42.03% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 103.37% |
| FCF Payout Ratio | 156.61% |
| Buyback Yield | -0.02% |
| Shareholder Yield | 3.30% |
| Earnings Yield | 3.17% |
| FCF Yield | 2.12% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for BioGaia AB is 158.00, which is 29.61% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 158.00 |
| Price Target Difference | 29.61% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | 11.23% |
| EPS Growth Forecast (3Y) | 18.54% |
Stock Splits
The last stock split was on May 18, 2022. It was a forward split with a ratio of 5.
| Last Split Date | May 18, 2022 |
| Split Type | Forward |
| Split Ratio | 5 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 5 |